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These findings suggest that, in addition to the current state of the art provided by modern cardiovascular therapeutics, novel therapeutic strategies reducing vascular inflammation will allow for targeting the residual cardiovascular risk. 1 Vascular inflammation has also been associated with and suggested as a trigger for the recycling of cellular components and organelles, a process known as autophagy (or autophagic flux). 2 This process is known to have a physiological role in endothelial cells and vascular smooth muscle cells (VSMCs), playing an integral role in the adaptive response to cellular stress and protecting against vascular calcification and apoptosis. 3 Despite a physiological role for autophagy in vascular biology, abnormally activated autophagy in vascular cells leads to local injury, cell death, and vascular disease pathogenesis. 2, 3 Autophagy contributes to atherogenesis through decreased plaque stability after autophagic death of VSMCs 3 and is in turn stimulated by atherogenic molecules (e.g. reactive oxygen species, oxidized low-density lipoprotein, and cytokines). 3 Important transcription factors and epigenetic modifications involved in cardiovascular disease pathogenesis, like forkhead box O (FoxO), have also been found to regulate autophagy. 4, 5 More specifically, histone deacetylases (HDACs), enzymes responsible for removing acetyl groups from lysine residues, 6 regulate autophagy in cardiovascular cells 7, 8 in addition to regulating the expression of genes involved in inflammatory signaling, metabolic disorders and hypertrophic responses. 6 Isoformspecific targeting of HDACs has been proposed as a therapeutic strategy in cardiovascular disease. 6 Although some isoforms of HDACs (e.g. sirtuins, or Class III HDACs) have been shown to have anti-inflammatory effects, 9 HDACs of Class II have been shown to promote autophagy 10 and pro-inflammatory vascular processes. 6 merely a secondary effect of vascular inflammation. To investigate a direct role for autophagy in vascular inflammation, the phosphatidylethanolamine-conjugated form of microtubule-associated protein light chain 3 (LC3-II) was silenced (by siRNA) or autophagic processes were inhibited pharmacologically (LY294002 or 3-methyladenine). Inhibiting or silencing autophagic processes both led to reduced vascular inflammation in Ang II models. Ang II-induced autophagy was also dependent on FoxO3a as silencing FoxO3a led to reduced Ang II-induced autophagic processes. Taken together, these findings are the first to describe a unique mechanism for the important role of HDAC4 in the regulation of Ang IIinduced autophagy and vascular inflammation via modification of key transcription factor FoxO3a (Figure 1 ). This study thus provides new avenues for exploration, including the direct regulation of autophagyrelated vascular inflammation and HDAC-related targeting.
Despite the potential of HDAC inhibition in mediating autophagydependent vascular inflammation, this study also raises crucial questions about autophagy that need to be further explored. Although Yang et al. increased vascular inflammation, a recent study has demonstrated that increasing autophagy via microRNA-100 reduces vascular inflammation. 12 These different views demonstrate that pathophysiological autophagy may not be simply a result of increased autophagy but also a change in the type of autophagy, dependent on its stimuli (e.g. microRNA, HDAC). 2 Further exploration will provide new insight into the different kinds of autophagic processes and then a more nuanced approach to targeting these processes may be developed accordingly.
Moreover, this study also raises exciting new questions to be explored in the future in the regulation of HDAC4 by oxidative stress. Epigenetic modifiers have been shown to be modulated by oxidative stress. Using an inhibitor of redox-sensitive transcription factor specificity protein (SP) 1 (mithramycin), the authors found that Ang II-induced increase in HDAC4 expression was suppressed with reduced activity of SP1, demonstrating inflammation-related increase in HDAC4 expression is SP1-mediated. This link of HDAC4 to redox-sensitive processes is Figure 1 Vascular inflammation is known to contribute to vascular biology and disease. In this study by Yang et al., 11 in a model of Ang II-induced vascular inflammation, Ang II-induction increases HDAC4 expression and autophagy. HDAC4, which is increasingly expressed with Ang II, mediates an increase in autophagy in inflammatory processes, at least partly, via deacetylation of transcription factor FoxO3a. Deacetylation of FoxO3a increases binding to autophagy gene promoters and ultimately increases expression of autophagic proteins LC3-II, Atg5, and Beclin 1. These proteins help coordinate autophagy, a process in which an autophagosome fuses with a lysosome to recycle cellular components (autophagic process redrawn on the basis of Fullgrabe et al.
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). In the resulting autolysosome, recycling occurs via lysosomal enzymes. This study demonstrates autophagy, which can also have physiological and maladaptive roles in vascular biology, has a causal role in inflammatory processes but the mechanism requires further exploration. Vascular inflammation also exists in a vicious cycle with oxidative stress, and HDAC4 expression itself is regulated by redox-sensitive transcription factor SP1. Thus, an important feedback mechanism may be at play between oxidative stress, epigenetic modifications by HDAC4, autophagy, and vascular inflammation that can provide further insight into the development and exacerbation of inflammation-related vascular disease. HDAC inhibitors selective for HDAC4 may help attenuate autophagy-related inflammation contributing to disease pathogenesis. Ang II, angiotensin II; AT 1 , angiotensin II receptor type 1; Atg5, autophagy related 5; FoxO3a, forkhead box O3a; HDAC4, histone deacetylase 4; LC3-II, phosphatidylethanolamine-conjugated form of microtubule-associated protein light chain 3; SP1, specificity protein 1. consistent with previous findings. 13 From this study's initial exploration of the redox-sensitivity of HDAC4, combined with previous knowledge that HDAC4 has redox-sensitive cysteine residues and is sensitive to protein kinase A and calcium/calmodulin-dependent protein kinase II, these new pathways may provide a crucial link between vascular oxidative stress and vascular inflammation. 14, 15 Given the exciting importance of these findings together, studies examining HDAC4's role in regulating vascular inflammation and oxidative stress in human vessels will provide further translational value. In conclusion, this study provides one crucial step forward in understanding epigenetic changes that mediate processes like inflammation in the vasculature, in this case particularly via autophagy-related pathways. Targeted inhibitors against specific Class IIa HDACs may be a very promising therapeutic approach in the future for autophagy-related vascular inflammation and disease as further research is conducted.
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